MedTrace Logo

Mass Balance and Biotransformation of [14C]HSK7653 in Human

NCT04540016 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-12-12

No results posted yet for this study

Summary

A single-center, single-dose, non-randomized, open-label design.

Conditions

  • Type II Diabetes

Interventions

DRUG

[14C]HSK7653

25 mg of \[14C\]HSK7653 (radioactivity of 80 µCi) capsules are taken under fasted condition.

Sponsors & Collaborators

  • First Affiliated Hospital of Suzhou Medical College

    collaborator OTHER

  • Sichuan Haisco Pharmaceutical Group Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Liyan Miao, PhD · Medical Ethics Committee of the First Affiliated Hospital of soochow University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-15
Primary Completion
2021-01-14
Completion
2021-01-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04540016 on ClinicalTrials.gov